Table 47Summary of included studies. Comparison 46. Augmenting with antipsychotic versus bupropion

StudyPopulationInterventionComparisonDetails of inadequate response/treatment resistanceComments

Cheon 2017

RCT

Korea

N=103

Mean age (years): 45.6

Gender (% female): 65

Ethnicity (% BME): NR

Baseline severity: MADRS 25.54 (more severe)

Aripiprazole 2.5-20mg/day + SSRIBupropion 150-300mg/day + SSRIInadequate response to 4 or more weeks with SSRIs

Treatment length (weeks): 6

Outcomes:

  • Depression symptomatology change score
  • Remission
  • Response
  • Discontinuation due to any reason
  • Discontinuation due to side effects

Mohamed 2017

RCT

US

N=1011

Mean age (years): 54.3

Gender (% female): 16

Ethnicity (% BME): 30

Baseline severity: QIDS 16.75 (more severe)

Aripiprazole 2-15mg/day + SSRI/SNRIBupropion 150-400mg/day + SSRI/SNRIInadequate response (QIDS score ≥16 after ≥6 weeks of treatment or score≥11 after ≥8 weeks of treatment with the 3 most recent weeks at a stable “optimal” dose) to a treatment course with a SSRI, SNRI, or mirtazapine that met or exceeded minimal standards for dose and duration of treatment

Treatment length (weeks): 12

Outcomes:

  • Remission
  • Response
  • Discontinuation due to any reason
  • Discontinuation due to side effects

BME: black and minority ethnic; MADRS: Montgomery-Asberg depression rating scale; NR: not reported; QIDS: quick inventory of depressive symptomatology; RCT: randomised controlled trial; SNRI: serotonin-norepinephrine reuptake inhibitor; SSRI: selective serotonin reuptake inhibitor

From: Further-line treatment

Cover of Further-line treatment
Further-line treatment: Depression in adults: Evidence review D.
NICE Guideline, No. 222.
Copyright © NICE 2022.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.